Fairvalue-Calculator Fairvalue-Calculator
EN DE

3D Global Biotech Inc (6808) Fair Value & Analysis

Healthcare · TW · Market cap 2.0B TWD

Price24.70 TWD
Fair Value11.76 TWD
Upside-52.4%
Quality95/100
Evidence: High Range 10.10 TWD – 14.80 TWD

Fair value as of: Jun 24, 2026

Analysis

3D Global Biotech Inc (6808) currently trades at 24.70 TWD, while our model-based Fair Value estimate is 11.76 TWD — implying the stock looks roughly 52.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

3D Global Biotech Inc. manufactures and sells medical devices for human body reconstruction. It offers artificial bone grafting; 3D bioForming; bio-dressing; 3D bioture EX; 3D printing equipment, such as 3D BioRealizer system; orthodontic aligner system under the SmileAlign name; and iMatrix, a sectional matrix kit. The company was founded in 2014 and is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is 3D Global Biotech Inc (6808) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 11.76 TWD versus a price of 24.70 TWD — about −52% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6808?
Our 21-model fair value for 3D Global Biotech Inc is 11.76 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 24.70 TWD.
What is the quality score of 6808?
3D Global Biotech Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.